Literature DB >> 15660243

Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.

Torsten Pfitzer1, Nathalie Niederhoffer, Bela Szabo.   

Abstract

Activation of CB(1) cannabinoid receptors by exogenous agonists causes presynaptic inhibition of neurotransmitter release from axon terminals. In the central nervous system, presynaptic CB(1) receptors can also be activated by endogenous cannabinoids (endocannabinoids) released from postsynaptic neurons. Except in the vas deferens, there is no indication of endocannabinoid-mediated presynaptic inhibition in the sympathetic nervous system. The aim of the present study was to search for such inhibition in pithed rats. Artificial sympathetic tone was established by continuous electrical stimulation of preganglionic sympathetic axons. The CB(1) cannabinoid receptor antagonist rimonabant (0.5 and 2 mg kg(-1) i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration. Since activation of Galpha(q/11) protein-coupled receptors enhances endocannabinoid synthesis in the central nervous system, we attempted to stimulate endocannabinoid production by infusion of arginine vasopressin and phenylephrine (both activate Galpha(q/11) protein-coupled receptors). Rimonabant (2 mg kg(-1) i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration during infusion of phenylephrine or vasopressin. In the final series of experiments we verified that an exogenous cannabinoid agonist produces sympathoinhibition. The synthetic CB(1)/CB(2) receptor agonist WIN55212-2 (0.1 and 1 mg kg(-1) i.v.) markedly lowered blood pressure and plasma noradrenaline concentration in pithed rats with electrically stimulated sympathetic outflow. In contrast, in pithed rats with a pressor infusion of noradrenaline, WIN55212-2 did not change blood pressure or heart rate. The results verify that activation of peripheral presynaptic CB(1) receptors inhibits noradrenaline release from sympathetic nerve terminals. The lack of effect of the CB(1) receptor antagonist rimonabant indicates that, even under conditions favouring endocannabinoid synthesis, endocannabinoid-mediated presynaptic inhibition is not operating in the sympathetic nervous system of the pithed rat.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660243     DOI: 10.1007/s00210-004-1003-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  43 in total

Review 1.  The endocannabinoid system as a target for therapeutic drugs.

Authors:  D Piomelli; A Giuffrida; A Calignano; F Rodríguez de Fonseca
Journal:  Trends Pharmacol Sci       Date:  2000-06       Impact factor: 14.819

Review 2.  Rimonabant Sanofi-Synthélabo.

Authors:  Jose R Fernandez; David B Allison
Journal:  Curr Opin Investig Drugs       Date:  2004-04

3.  Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid.

Authors:  R Mechoulam; E Fride; S Ben-Shabat; U Meiri; M Horowitz
Journal:  Eur J Pharmacol       Date:  1998-11-27       Impact factor: 4.432

4.  Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors.

Authors:  A A Izzo; N Mascolo; F Borrelli; F Capasso
Journal:  Br J Pharmacol       Date:  1998-08       Impact factor: 8.739

5.  Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor.

Authors:  Jianping Li; Norbert E Kaminski; Donna H Wang
Journal:  Hypertension       Date:  2002-12-30       Impact factor: 10.190

6.  Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.

Authors:  D Gebremedhin; A R Lange; W B Campbell; C J Hillard; D R Harder
Journal:  Am J Physiol       Date:  1999-06

7.  Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 8.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

9.  Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension.

Authors:  K Varga; J A Wagner; D T Bridgen; G Kunos
Journal:  FASEB J       Date:  1998-08       Impact factor: 5.191

10.  Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse.

Authors:  I Wallmichrath; B Szabo
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

View more
  18 in total

1.  Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

Authors:  Grzegorz Godlewski; Barbara Malinowska; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

3.  Circulating endocannabinoid concentrations during orthostatic stress.

Authors:  Christoph Schroeder; Sandor Batkai; Stefan Engeli; Jens Tank; André Diedrich; Friedrich C Luft; Jens Jordan
Journal:  Clin Auton Res       Date:  2009-12       Impact factor: 4.435

Review 4.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 5.  Stress regulates endocannabinoid-CB1 receptor signaling.

Authors:  Cecilia J Hillard
Journal:  Semin Immunol       Date:  2014-05-29       Impact factor: 11.130

6.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

7.  Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.

Authors:  T Schultheiss; K Flau; M Kathmann; M Göthert; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-30       Impact factor: 3.000

Review 8.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

9.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.